Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma

Opinion statement Advanced basal cell carcinoma (BCC) represents a small proportion of BCCs that are not amenable to standard therapies due to lack of efficacy, high recurrence risk, and excessive morbidity. Implication of the Sonic hedgehog (Shh) pathway in the development of BCC has led to the dev...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current treatment options in oncology 2019-11, Vol.20 (11), p.84-84, Article 84
Hauptverfasser: Leavitt, Erica, Lask, Gary, Martin, Stephanie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 84
container_issue 11
container_start_page 84
container_title Current treatment options in oncology
container_volume 20
creator Leavitt, Erica
Lask, Gary
Martin, Stephanie
description Opinion statement Advanced basal cell carcinoma (BCC) represents a small proportion of BCCs that are not amenable to standard therapies due to lack of efficacy, high recurrence risk, and excessive morbidity. Implication of the Sonic hedgehog (Shh) pathway in the development of BCC has led to the development of systemic Shh pathway inhibitors, providing patients with advanced BCCs new treatment options and improved survival. There are currently two Food and Drug Administration (FDA)–approved Shh inhibitors, vismodegib and sonidegib, for advanced basal cell carcinomas. Vismodegib has approval for locally advanced BCCs (laBCC) and metastatic BCC (mBCC), while sonidegib has approval for laBCC. These agents have also been used for prevention in nevoid basal cell carcinoma syndrome and as neoadjuvant therapy before surgery, and we feel that there is a growing role of Shh inhibitors in these settings. Head-to-head randomized controlled trials comparing vismodegib to sonidegib are lacking. Adverse events can limit the utility of these medications by leading to treatment discontinuation in a large proportion of patients, and it is thus essential that prescribers be able to anticipate and manage the most frequent side effects of muscle spasms, alopecia, dysgeusia, nausea, and weight loss. Other Shh inhibitors, including the antifungal itraconazole, have been investigated in small trials, but further research is needed before recommending their routine clinical use. Additionally, there are several new agents under investigation that may have improved efficacy for resistant tumors by utilizing different mechanisms of action than the two currently approved medications.
doi_str_mv 10.1007/s11864-019-0683-9
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2319196897</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2319196897</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-b223e55113075eabedfd070920b1676c556df2adb62978c40b7c62bfef2104b43</originalsourceid><addsrcrecordid>eNp9kE9PAjEQxRujEUQ_gBfTo5fV_tlt6RGJCgmJJuC5abuzsIRtsV00fHuXgB69zEwy773M_BC6peSBEiIfE6VDkWeEqoyIIc_UGerTgueZYFKeH2YmMyaZ6qGrlNaEsCIn6hL1OJWSc6n6aD4PvnZ4AuUSVmGJ3027-jZ7PPWr2tZtHTyuPW5XgBcRTNuAb3Go8Kj8Mt5BiZ9MMhs8hk1XTHS1D425RheV2SS4OfUB-nh5Xown2eztdToezTKXU9JmljEORUEpJ7IAY6GsSiKJYsRSIYUrClFWzJRWMCWHLidWOsFsBRWjJLc5H6D7Y-42hs8dpFY3dXLdKcZD2CXNOFVUiaGSnZQepS6GlCJUehvrxsS9pkQfWOojS92x1AeWWnWeu1P8zjZQ_jl-4XUCdhSkbuWXEPU67KLvXv4n9QdHQn4a</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2319196897</pqid></control><display><type>article</type><title>Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma</title><source>SpringerNature Journals</source><creator>Leavitt, Erica ; Lask, Gary ; Martin, Stephanie</creator><creatorcontrib>Leavitt, Erica ; Lask, Gary ; Martin, Stephanie</creatorcontrib><description>Opinion statement Advanced basal cell carcinoma (BCC) represents a small proportion of BCCs that are not amenable to standard therapies due to lack of efficacy, high recurrence risk, and excessive morbidity. Implication of the Sonic hedgehog (Shh) pathway in the development of BCC has led to the development of systemic Shh pathway inhibitors, providing patients with advanced BCCs new treatment options and improved survival. There are currently two Food and Drug Administration (FDA)–approved Shh inhibitors, vismodegib and sonidegib, for advanced basal cell carcinomas. Vismodegib has approval for locally advanced BCCs (laBCC) and metastatic BCC (mBCC), while sonidegib has approval for laBCC. These agents have also been used for prevention in nevoid basal cell carcinoma syndrome and as neoadjuvant therapy before surgery, and we feel that there is a growing role of Shh inhibitors in these settings. Head-to-head randomized controlled trials comparing vismodegib to sonidegib are lacking. Adverse events can limit the utility of these medications by leading to treatment discontinuation in a large proportion of patients, and it is thus essential that prescribers be able to anticipate and manage the most frequent side effects of muscle spasms, alopecia, dysgeusia, nausea, and weight loss. Other Shh inhibitors, including the antifungal itraconazole, have been investigated in small trials, but further research is needed before recommending their routine clinical use. Additionally, there are several new agents under investigation that may have improved efficacy for resistant tumors by utilizing different mechanisms of action than the two currently approved medications.</description><identifier>ISSN: 1527-2729</identifier><identifier>EISSN: 1534-6277</identifier><identifier>DOI: 10.1007/s11864-019-0683-9</identifier><identifier>PMID: 31773379</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Medicine ; Medicine &amp; Public Health ; Oncology ; Section Editor ; Skin Cancer (T Ito ; Topical Collection on Skin Cancer</subject><ispartof>Current treatment options in oncology, 2019-11, Vol.20 (11), p.84-84, Article 84</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-b223e55113075eabedfd070920b1676c556df2adb62978c40b7c62bfef2104b43</citedby><cites>FETCH-LOGICAL-c410t-b223e55113075eabedfd070920b1676c556df2adb62978c40b7c62bfef2104b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11864-019-0683-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11864-019-0683-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31773379$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leavitt, Erica</creatorcontrib><creatorcontrib>Lask, Gary</creatorcontrib><creatorcontrib>Martin, Stephanie</creatorcontrib><title>Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma</title><title>Current treatment options in oncology</title><addtitle>Curr. Treat. Options in Oncol</addtitle><addtitle>Curr Treat Options Oncol</addtitle><description>Opinion statement Advanced basal cell carcinoma (BCC) represents a small proportion of BCCs that are not amenable to standard therapies due to lack of efficacy, high recurrence risk, and excessive morbidity. Implication of the Sonic hedgehog (Shh) pathway in the development of BCC has led to the development of systemic Shh pathway inhibitors, providing patients with advanced BCCs new treatment options and improved survival. There are currently two Food and Drug Administration (FDA)–approved Shh inhibitors, vismodegib and sonidegib, for advanced basal cell carcinomas. Vismodegib has approval for locally advanced BCCs (laBCC) and metastatic BCC (mBCC), while sonidegib has approval for laBCC. These agents have also been used for prevention in nevoid basal cell carcinoma syndrome and as neoadjuvant therapy before surgery, and we feel that there is a growing role of Shh inhibitors in these settings. Head-to-head randomized controlled trials comparing vismodegib to sonidegib are lacking. Adverse events can limit the utility of these medications by leading to treatment discontinuation in a large proportion of patients, and it is thus essential that prescribers be able to anticipate and manage the most frequent side effects of muscle spasms, alopecia, dysgeusia, nausea, and weight loss. Other Shh inhibitors, including the antifungal itraconazole, have been investigated in small trials, but further research is needed before recommending their routine clinical use. Additionally, there are several new agents under investigation that may have improved efficacy for resistant tumors by utilizing different mechanisms of action than the two currently approved medications.</description><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncology</subject><subject>Section Editor</subject><subject>Skin Cancer (T Ito</subject><subject>Topical Collection on Skin Cancer</subject><issn>1527-2729</issn><issn>1534-6277</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kE9PAjEQxRujEUQ_gBfTo5fV_tlt6RGJCgmJJuC5abuzsIRtsV00fHuXgB69zEwy773M_BC6peSBEiIfE6VDkWeEqoyIIc_UGerTgueZYFKeH2YmMyaZ6qGrlNaEsCIn6hL1OJWSc6n6aD4PvnZ4AuUSVmGJ3027-jZ7PPWr2tZtHTyuPW5XgBcRTNuAb3Go8Kj8Mt5BiZ9MMhs8hk1XTHS1D425RheV2SS4OfUB-nh5Xown2eztdToezTKXU9JmljEORUEpJ7IAY6GsSiKJYsRSIYUrClFWzJRWMCWHLidWOsFsBRWjJLc5H6D7Y-42hs8dpFY3dXLdKcZD2CXNOFVUiaGSnZQepS6GlCJUehvrxsS9pkQfWOojS92x1AeWWnWeu1P8zjZQ_jl-4XUCdhSkbuWXEPU67KLvXv4n9QdHQn4a</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Leavitt, Erica</creator><creator>Lask, Gary</creator><creator>Martin, Stephanie</creator><general>Springer US</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20191101</creationdate><title>Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma</title><author>Leavitt, Erica ; Lask, Gary ; Martin, Stephanie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-b223e55113075eabedfd070920b1676c556df2adb62978c40b7c62bfef2104b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncology</topic><topic>Section Editor</topic><topic>Skin Cancer (T Ito</topic><topic>Topical Collection on Skin Cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leavitt, Erica</creatorcontrib><creatorcontrib>Lask, Gary</creatorcontrib><creatorcontrib>Martin, Stephanie</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current treatment options in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leavitt, Erica</au><au>Lask, Gary</au><au>Martin, Stephanie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma</atitle><jtitle>Current treatment options in oncology</jtitle><stitle>Curr. Treat. Options in Oncol</stitle><addtitle>Curr Treat Options Oncol</addtitle><date>2019-11-01</date><risdate>2019</risdate><volume>20</volume><issue>11</issue><spage>84</spage><epage>84</epage><pages>84-84</pages><artnum>84</artnum><issn>1527-2729</issn><eissn>1534-6277</eissn><abstract>Opinion statement Advanced basal cell carcinoma (BCC) represents a small proportion of BCCs that are not amenable to standard therapies due to lack of efficacy, high recurrence risk, and excessive morbidity. Implication of the Sonic hedgehog (Shh) pathway in the development of BCC has led to the development of systemic Shh pathway inhibitors, providing patients with advanced BCCs new treatment options and improved survival. There are currently two Food and Drug Administration (FDA)–approved Shh inhibitors, vismodegib and sonidegib, for advanced basal cell carcinomas. Vismodegib has approval for locally advanced BCCs (laBCC) and metastatic BCC (mBCC), while sonidegib has approval for laBCC. These agents have also been used for prevention in nevoid basal cell carcinoma syndrome and as neoadjuvant therapy before surgery, and we feel that there is a growing role of Shh inhibitors in these settings. Head-to-head randomized controlled trials comparing vismodegib to sonidegib are lacking. Adverse events can limit the utility of these medications by leading to treatment discontinuation in a large proportion of patients, and it is thus essential that prescribers be able to anticipate and manage the most frequent side effects of muscle spasms, alopecia, dysgeusia, nausea, and weight loss. Other Shh inhibitors, including the antifungal itraconazole, have been investigated in small trials, but further research is needed before recommending their routine clinical use. Additionally, there are several new agents under investigation that may have improved efficacy for resistant tumors by utilizing different mechanisms of action than the two currently approved medications.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>31773379</pmid><doi>10.1007/s11864-019-0683-9</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1527-2729
ispartof Current treatment options in oncology, 2019-11, Vol.20 (11), p.84-84, Article 84
issn 1527-2729
1534-6277
language eng
recordid cdi_proquest_miscellaneous_2319196897
source SpringerNature Journals
subjects Medicine
Medicine & Public Health
Oncology
Section Editor
Skin Cancer (T Ito
Topical Collection on Skin Cancer
title Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T08%3A48%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sonic%20Hedgehog%20Pathway%20Inhibition%20in%20the%20Treatment%20of%20Advanced%20Basal%20Cell%20Carcinoma&rft.jtitle=Current%20treatment%20options%20in%20oncology&rft.au=Leavitt,%20Erica&rft.date=2019-11-01&rft.volume=20&rft.issue=11&rft.spage=84&rft.epage=84&rft.pages=84-84&rft.artnum=84&rft.issn=1527-2729&rft.eissn=1534-6277&rft_id=info:doi/10.1007/s11864-019-0683-9&rft_dat=%3Cproquest_cross%3E2319196897%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2319196897&rft_id=info:pmid/31773379&rfr_iscdi=true